R1 RCM Inc. provides revenue cycle management (RCM) for healthcare providers in the United States. The company offers end-to-end RCM services to manage their revenue cycle operations that encompass patient registration, insurance and benefit verification, medical treatment documentation and coding, bill preparation, and collections from patients and payers. It also provides modular services comprising physician advisory services, which assists healthcare organizations in complying with payer requirements regarding whether to classify a hospital visit as an in-patient or an out-patient observation case for billing purposes; practice management services that offers administrative and operational support for patient care and outsource non-core functions; revenue integrity solutions, including charge capture, charge description master maintenance, and pricing services; coding management services, such as business intelligence and analysis, human capital management, accountability framework, and quality management programs; patient experience; and business office services. In addition, the company offers software-as-a-service based scheduling and patient access solutions. It serves healthcare providers, including health systems, hospitals, and physician groups. The company was formerly known as Accretive Health, Inc. and changed its name to R1 RCM Inc. in January 2017. R1 RCM Inc. was incorporated in 2003 and is headquartered in Chicago, Illinois.
IPO Year:
Exchange: NASDAQ
Website: r1rcm.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/8/2024 | Overweight → Equal-Weight | Morgan Stanley | |
| 8/1/2024 | Overweight → Equal-Weight | Stephens | |
| 8/1/2024 | Outperform → Market Perform | Leerink Partners | |
| 8/1/2024 | Buy → Hold | Jefferies | |
| 4/10/2024 | Overweight → Sector Weight | KeyBanc Capital Markets | |
| 3/20/2024 | $16.00 | Neutral → Buy | Citigroup |
| 2/26/2024 | $14.00 | Outperform | Leerink Partners |
| 1/3/2024 | $14.00 | Overweight | Barclays |
| 12/15/2023 | $17.50 → $17.00 | Equal-Weight → Overweight | Morgan Stanley |
| 12/13/2023 | $20.00 → $11.00 | Overweight → Neutral | JP Morgan |
SC 13D/A - R1 RCM Inc. /DE (0001910851) (Subject)
SC 13D/A - R1 RCM Inc. /DE (0001910851) (Subject)
SC 13D/A - R1 RCM Inc. /DE (0001910851) (Subject)
SC 13D/A - R1 RCM Inc. /DE (0001910851) (Subject)
SC 13D/A - R1 RCM Inc. /DE (0001910851) (Subject)
SC 13D/A - R1 RCM Inc. /DE (0001910851) (Subject)
SC 13D/A - R1 RCM Inc. /DE (0001910851) (Subject)
SC 13D/A - R1 RCM Inc. /DE (0001910851) (Subject)
SC 13D - R1 RCM Inc. /DE (0001910851) (Subject)
SC 13D/A - R1 RCM Inc. /DE (0001910851) (Subject)
POSASR - R1 RCM Inc. /DE (0001910851) (Filer)
S-8 POS - R1 RCM Inc. /DE (0001910851) (Filer)
S-8 POS - R1 RCM Inc. /DE (0001910851) (Filer)
S-8 POS - R1 RCM Inc. /DE (0001910851) (Filer)
SC 13E3/A - R1 RCM Inc. /DE (0001910851) (Subject)
8-K - R1 RCM Inc. /DE (0001910851) (Filer)
25-NSE/A - R1 RCM Inc. /DE (0001910851) (Subject)
25-NSE - R1 RCM Inc. /DE (0001910851) (Subject)
8-K - R1 RCM Inc. /DE (0001910851) (Filer)
10-Q - R1 RCM Inc. /DE (0001910851) (Filer)
MURRAY, Utah, Nov. 05, 2024 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ:RCM) ("R1" or the "Company"), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced results for the three months ended September 30, 2024. Third Quarter 2024 Results: Revenue of $656.8 million, up $84.0 million or 14.7% compared to the same period last year.GAAP net loss of $19.9 million, compared to net income of $1.3 million in the same period last year.Adjusted EBITDA of $148.2 million, compared to adjusted EBITDA of $161.5 million in the same period last year. The quarter reflects impacts to both revenue and costs as
MURRAY, Utah, Aug. 07, 2024 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ:RCM) ("R1" or the "Company"), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced results for the three months ended June 30, 2024. Second Quarter 2024 Results: Revenue of $627.9 million, up $67.2 million or 12.0% compared to the same period last year.GAAP net loss of $7.6 million, compared to net loss of $1.0 million in the same period last year.Adjusted EBITDA of $156.1 million, compared to adjusted EBITDA of $142.9 million in the same period last year. The quarte
MURRAY, Utah, Aug. 01, 2024 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ:RCM) ("R1" or the "Company"), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced that it has entered into a definitive agreement to be acquired by investment funds affiliated with TowerBrook Capital Partners and Clayton, Dubilier & Rice ("CD&R"), in an all-cash transaction with an enterprise value of approximately $8.9 billion. An investment vehicle controlled by TowerBrook is currently the beneficial owner of approximately 36% of the Company's outstanding shares of common stock, including the warrant held by TowerBrook.
MURRAY, Utah, July 15, 2024 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ:RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced it expects to release financial results for the three months ended June 30, 2024, before market open on Wednesday, August 7, 2024 and host a conference call at 8:00 a.m. ET to review the results. Investors and other interested parties are invited to listen to the conference call by dialing 888-596-4144 (646-968-2525 outside the U.S. and Canada) using conference code number 9123341. A live webcast and replay of the call will be available at the Investor Relations s
MURRAY, Utah, May 08, 2024 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ:RCM) ("R1" or the "Company"), a leading provider of technology-driven solutions that transform the financial performance and patient experience for health systems, hospitals, and physician groups, today announced results for the three months ended March 31, 2024 and updated full year 2024 outlook. First Quarter 2024 Results: Revenue of $603.9 million, up $58.3 million or 10.7% compared to the same period last year.GAAP net loss of $35.1 million, compared to net income of $1.6 million in the same period last year.Adjusted EBITDA of $152.2 million, compared to adjusted EBI
MURRAY, Utah, April 01, 2024 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ:RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced it expects to release financial results for the three months ended March 31, 2024, before market open on Wednesday, May 8, 2024 and host a conference call at 8:00 a.m. ET to review the results. Investors and other interested parties are invited to listen to the conference call by dialing 888-596-4144 (646-968-2525 outside the U.S. and Canada) using conference code number 9123341. A live webcast and replay of the call will be available at the Investor Relations
MURRAY, Utah, Feb. 27, 2024 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ:RCM) ("R1" or the "Company"), a leading provider of technology-driven solutions that transform the financial performance and patient experience for health systems, hospitals, and physician groups, today announced results for the three months and year ended December 31, 2023. Fourth Quarter 2023 Results: Revenue of $575.1 million, up $41.8 million or 7.8% compared to the same period last yearGAAP net income of $1.4 million, compared to a net loss of $36.6 million in the same period last yearAdjusted EBITDA of $167.7 million, up $42.1 million or 33.5% compared to the same period last year Full Year 2023 Results: Revenue
Company Enters 10-Year Agreement to Provide Comprehensive Revenue Cycle Management Services to Providence Company to Release Fourth Quarter and Full Year 2023 Financial Results and 2024 Financial Outlook on February 27, 2024 MURRAY, Utah, Jan. 17, 2024 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ:RCM) ("R1"), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced that it has completed its previously announced acquisition of Acclara from Providence, one of the nation's largest health systems. In addition, the Company announced that it expects to release financial results for the fourth quarter a
Acquisition of Providence's Current Modular Services Business Accompanied by 10-Year Agreement to Provide Comprehensive Revenue Cycle Management Services R1 to Host Conference Call Today at 8:00 AM ET MURRAY, Utah, Dec. 06, 2023 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ:RCM) ("R1"), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced that it has entered into a definitive agreement to acquire Acclara, a leading technology-driven revenue cycle management company, from Providence, one of the nation's largest health systems; and the Company has been selected by Providence as its long-term re
MURRAY, Utah, Nov. 02, 2023 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ:RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced results for the three months ended September 30, 2023. Third Quarter 2023 Results: Revenue of $572.8 million, up $76.8 million or 15.5% compared to the same period last year.GAAP net income of $1.3 million, compared to net loss of $29.5 million in the same period last year.Adjusted EBITDA of $161.5 million, up $37.5 million or 30.2% compared to the same period last year. "Our strong third quarter results demonstrate our team's dedication to innovatio
MURRAY, Utah, Nov. 19, 2024 (GLOBE NEWSWIRE) -- R1 RCM Inc. ("R1"), a leader in automating revenue management for healthcare providers, today announced that investment funds affiliated with TowerBrook Capital Partners ("TowerBrook") and Clayton, Dubilier & Rice ("CD&R") have completed their previously announced acquisition of R1. On August 1, 2024, TowerBrook, CD&R and R1 announced that they had entered into a definitive merger agreement under which all outstanding shares of R1 common stock that TowerBrook did not own would be acquired for $14.30 per share in cash, valuing R1 at approximately $8.9 billion. With the completion of the transaction, R1's common stock has ceased trading and w
NEW YORK, Nov. 15, 2024 /PRNewswire/ -- Shift4 Payments Inc. (NYSE:FOUR) will replace R1 RCM Inc. (NASD:RCM) in the S&P MidCap 400 effective prior to the opening of trading on Wednesday, November 20. TowerBrook Capital Partners and Clayton, Dublier & Rice will acquire R1 RCM in a transaction expected to be completed on or about November 19. Following is a summary of the change that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector November 20, 2024 S&P MidCap 400 Addition Shift4 Payments FOUR Financials S&P MidCap 400 Deletion R1 RCM RCM Health Care For more information about S&P Dow Jones Indices, ple
MURRAY, Utah, Nov. 05, 2024 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ:RCM) ("R1" or the "Company"), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced results for the three months ended September 30, 2024. Third Quarter 2024 Results: Revenue of $656.8 million, up $84.0 million or 14.7% compared to the same period last year.GAAP net loss of $19.9 million, compared to net income of $1.3 million in the same period last year.Adjusted EBITDA of $148.2 million, compared to adjusted EBITDA of $161.5 million in the same period last year. The quarter reflects impacts to both revenue and costs as
MURRAY, Utah, Aug. 07, 2024 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ:RCM) ("R1" or the "Company"), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced results for the three months ended June 30, 2024. Second Quarter 2024 Results: Revenue of $627.9 million, up $67.2 million or 12.0% compared to the same period last year.GAAP net loss of $7.6 million, compared to net loss of $1.0 million in the same period last year.Adjusted EBITDA of $156.1 million, compared to adjusted EBITDA of $142.9 million in the same period last year. The quarte
MURRAY, Utah, Aug. 01, 2024 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ:RCM) ("R1" or the "Company"), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced that it has entered into a definitive agreement to be acquired by investment funds affiliated with TowerBrook Capital Partners and Clayton, Dubilier & Rice ("CD&R"), in an all-cash transaction with an enterprise value of approximately $8.9 billion. An investment vehicle controlled by TowerBrook is currently the beneficial owner of approximately 36% of the Company's outstanding shares of common stock, including the warrant held by TowerBrook.
MURRAY, Utah, July 24, 2024 (GLOBE NEWSWIRE) -- The Special Committee of the R1 RCM Inc. (NASDAQ:RCM) ("R1" or the "Company") Board of Directors, which comprises independent directors and was formed to evaluate strategic alternatives in response to the Schedule 13D/A filed by New Mountain Capital, L.L.C. ("New Mountain Capital") with the Securities and Exchange Commission on February 26, 2024, today announced it has set a final deadline for interested parties to submit fully-financed bids on July 31, 2024 in connection with its review process. No assurances can be given regarding the outcome or timing of the Special Committee's review process. The Special Committee continues to evaluate a
MURRAY, Utah, July 15, 2024 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ:RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced it expects to release financial results for the three months ended June 30, 2024, before market open on Wednesday, August 7, 2024 and host a conference call at 8:00 a.m. ET to review the results. Investors and other interested parties are invited to listen to the conference call by dialing 888-596-4144 (646-968-2525 outside the U.S. and Canada) using conference code number 9123341. A live webcast and replay of the call will be available at the Investor Relations s
MURRAY, Utah, June 17, 2024 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ:RCM) ("R1" or the "Company"), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced it will host a virtual event on Thursday, June 27, 2024 at 11:00 AM ET. To register, click here. The event will feature Steve Albert, Executive Vice President and Chief Product Officer, and Brian Gambs, Executive Vice President and Chief Technology Officer. Steve and Brian will provide an overview of the R1 Platform and key areas of innovation as well as value creation for R1 and its customers. They will also highlight key advantages of the
MURRAY, Utah, May 24, 2024 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ:RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced its management team will present at the 2024 Jefferies Global Healthcare Conference on Wednesday, June 5, 2024, at 10:30am ET. A live audio webcast of this presentation will be available on the Investor Relations section of R1's website at r1rcm.com. A replay of the webcast will be available for 90 days following the live webcast. About R1 RCM R1 is a leading provider of technology-driven solutions that transform the patient experience and financial performance of
MURRAY, Utah, May 08, 2024 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ:RCM) ("R1" or the "Company"), a leading provider of technology-driven solutions that transform the financial performance and patient experience for health systems, hospitals, and physician groups, today announced results for the three months ended March 31, 2024 and updated full year 2024 outlook. First Quarter 2024 Results: Revenue of $603.9 million, up $58.3 million or 10.7% compared to the same period last year.GAAP net loss of $35.1 million, compared to net income of $1.6 million in the same period last year.Adjusted EBITDA of $152.2 million, compared to adjusted EBI
Morgan Stanley downgraded R1 RCM from Overweight to Equal-Weight
Stephens downgraded R1 RCM from Overweight to Equal-Weight
Leerink Partners downgraded R1 RCM from Outperform to Market Perform
Jefferies downgraded R1 RCM from Buy to Hold
KeyBanc Capital Markets downgraded R1 RCM from Overweight to Sector Weight
Citigroup upgraded R1 RCM from Neutral to Buy and set a new price target of $16.00
Leerink Partners initiated coverage of R1 RCM with a rating of Outperform and set a new price target of $14.00
Barclays initiated coverage of R1 RCM with a rating of Overweight and set a new price target of $14.00
Morgan Stanley upgraded R1 RCM from Equal-Weight to Overweight and set a new price target of $17.00 from $17.50 previously
JP Morgan downgraded R1 RCM from Overweight to Neutral and set a new price target of $11.00 from $20.00 previously
NEW YORK, Nov. 15, 2024 /PRNewswire/ -- Shift4 Payments Inc. (NYSE:FOUR) will replace R1 RCM Inc. (NASD:RCM) in the S&P MidCap 400 effective prior to the opening of trading on Wednesday, November 20. TowerBrook Capital Partners and Clayton, Dublier & Rice will acquire R1 RCM in a transaction expected to be completed on or about November 19. Following is a summary of the change that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector November 20, 2024 S&P MidCap 400 Addition Shift4 Payments FOUR Financials S&P MidCap 400 Deletion R1 RCM RCM Health Care For more information about S&P Dow Jones Indices, ple
Rachel Wilson appointed as Chief Financial Officer (CFO) James Hardie Industries plc ((ASX: JHX, NYSE:JHX), the world's #1 producer and marketer of high-performance fiber cement and fiber gypsum building solutions, today announced the appointment of Ms. Rachel Wilson as Chief Financial Officer, effective immediately. As a member of the global executive team, Ms. Wilson will report directly to Chief Executive Officer Aaron Erter. Ms. Wilson was appointed after Jason Miele stepped down as Chief Financial Officer. Mr. Miele will remain with the Company for three months as an advisor to the Chief Executive Officer for special projects and will thereafter depart the organization. "I would li
MURRAY, Utah, Aug. 12, 2021 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ:RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced the appointment of Agnes Bundy Scanlan, president of The Cambridge Group LLC, to the company's board of directors, effective August 11, 2021. Ms. Bundy Scanlan has more than 30 years of experience across regulatory risk management, compliance, and consumer financial protection. She has served as president of The Cambridge Group LLC, a regulatory risk management advisory firm, since May 2020. Prior to this role, Ms. Bundy Scanlan served as senior advisor at Trelian
MURRAY, Utah, Aug. 02, 2021 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ:RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced that Jay Sreedharan will join the executive team as its first chief technology and digital officer. Sreedharan will lead R1's efforts in creating digital solutions that drive higher-value experiences for patients and providers. In this role, Sreedharan will be responsible for delivering on R1's promise of digital transformation and growth, including strategy, engineering, product development, architecture and implementation, as well as future digital M&A and partn
Conversion of Preferred Stock to Shares of Common Stock to Enhance Alignment with Common Shareholders Ascension and TowerBrook Committed to Supporting Sustainable Long-Term Growth CHICAGO, Jan. 06, 2021 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-enabled revenue cycle management services to healthcare providers, announced that it has entered into an agreement with TCP-ASC ACHI Series LLLP, an investment vehicle jointly owned by Ascension Health Alliance (“Ascension”) and investment funds affiliated with TowerBrook Capital Partners L.P. (“TowerBrook”), for the conversion of all of the 8.00% Series A Convertible Preferred Stock (the “Preferre
4 - R1 RCM Inc. /DE (0001910851) (Issuer)
4 - R1 RCM Inc. /DE (0001910851) (Issuer)
4 - R1 RCM Inc. /DE (0001910851) (Issuer)
4 - R1 RCM Inc. /DE (0001910851) (Issuer)
4 - R1 RCM Inc. /DE (0001910851) (Issuer)
4 - R1 RCM Inc. /DE (0001910851) (Issuer)
4 - R1 RCM Inc. /DE (0001910851) (Issuer)
4 - R1 RCM Inc. /DE (0001910851) (Issuer)
4 - R1 RCM Inc. /DE (0001910851) (Issuer)
4 - R1 RCM Inc. /DE (0001910851) (Issuer)